Completed PHASE1 INTERVENTIONAL 2-arm NCT05328726

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

A Double-blind, Randomized, Placebo-controlled, Sequential, Single, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of Subcutaneous Injections of GZR18 in Healthy Subjects

Sponsor: Gan and Lee Pharmaceuticals, USA

Conditions Diabetes Mellitus, Type 2

Interventions GZR-18 Placebo

Updated 5 times since 2022 Last updated: Mar 22, 2023 Started: Mar 8, 2022 Primary completion: Feb 9, 2023 Completion: Mar 9, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Gan and Lee Pharmaceuticals, USA leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2023 — Apr 2023 [monthly]

Recruiting PHASE1
May 2022 — Jan 2023 [monthly]

Recruiting PHASE1

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gan and Lee Pharmaceuticals, USA

Data source: Gan and Lee Pharmaceuticals, USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States